Author Archive for: TG

According to a new deal, AGC Biologics wil manufacture AAVantgarde’s dual AAV gene therapies for inherited retinal diseases using the high-yield BravoAAV™ suspension platform.

Roche has reported that its selective estrogen receptor degrader (SERD), giredestrant, has demonstrated significant clinical benefit in pivotal Phase III trials for adjuvant early-stage ER-positive, HER2-negative breast cancer, as well as strong efficacy in advanced breast cancer settings. These results position giredestrant as the first oral SERD to show meaningful clinical benefit in this indication. The announcement sparked a notable 7% jump in Roche’s share price in a single day.

The company Captain T Cell, spin-out from Max-Delbrück center in Berlin, now has a total of €20 million in funding and grants to push forward its novel cell therapies for solid tumours. New backers include Springboard Health Angels, Pluton Asset Holding, Sintra Limited and the Technologiegründerfonds Sachsen, joining the existing investor base. The new tennant in Bayer´s Co.Lab in Berlin City does starts with positive vibes.

Sofinnova Partners has closed its new investment fund, Capital XI, at €650m, far exceeding its original target. The early-stage biotech and medtech-focused fund will invest mostly in Series A, but also seed financings of companies, including oncology, inflammation and immunology, CNS, and cardio-metabolic diseases.

Swiss biotech Virometix has raised US$15m in fresh funding to accelerate development of its lead pneumococcal vaccine candidate and advance its next-generation synthetic vaccine platform.